

Board Changes

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company") is pleased to announce it has appointed Mr Robert Maxwell Johnston as a Non-Executive Director.

Prior to his non-executive director career, Mr Johnston held the position of President and Chief Executive officer of Johnson and Johnson Pacific, a division of the world's largest healthcare company for 11 years.

Prior to this appointment, his career included several positions within Johnson and Johnson, both within Australia and overseas encompassing Europe and Asia. Mr Johnston's career also included senior roles within Australia and overseas with Unilever and Guinness-United Distillers and several prominent industry body roles as past President of ACCORD Australasia Limited, Vice Chairman of AFGC, and Board Member of ASML.

Mr Johnston is currently a Non-executive Director of Inovia Ltd (ASX: IIQ) and was a former Non-executive director of PolyNovo Ltd (ASX: PNV), Medical Developments International Limited (ASX: MVP), Tissue Repair Ltd (ASX: TRP), Eneo Group Limited (ASX: EGG), Non-executive Chairman of Probiotec Ltd (ASX: PBP), Non-executive Chairman of AusCann Pty Ltd (ASX: AC8). He also acted as interim CEO of PolyNovo from November 2021 to August 2022.

Subject to shareholder approval, the Company agreed to issue 1,000,000 options to Mr Johnston (or his nominee) as an equity based incentive component to his remuneration package. These options will be issued on the same material terms as the Company's attaching options under the placement announced on 17 April 2024 ("Attaching Options"). The Attaching Options will have a strike price of \$0.16 and will expire two years from the date of their issue.

The Company further advises that Non-Executive Director, Winton Willesee has resigned from his position on the Board, effective from the date of this announcement.

The Company would like to take this opportunity to welcome Mr Johnston to the Board. The Company also thanks Mr Willesee for his valuable contributions to the Company during his time in office since his appointment to the board in April 2019.

Authority

This announcement has been authorised for release by the Board of Neurotech International Limited.

Further Information

Dr Thomas Duthy
Executive Director
td@neurotechinternational.com
+61 (0)402 493 727

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders. Neurotech has completed a Phase I/II clinical trial in Autism Spectrum Disorder (ASD), which demonstrated excellent safety and efficacy results at 28 days, 20 weeks and 52 weeks of treatment with NTI164. The Company has

completed recruitment for a Phase II/III randomised, double-blind, placebo-controlled clinical trial in ASD and a Phase I/II trial in Rett Syndrome and reported Phase I/II clinical trial data in Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS. In addition, Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.